Skip to main content
Erschienen in: Abdominal Radiology 10/2019

09.08.2019 | Kidneys, Ureters, Bladder, Retroperitoneum

Baseline perfusion CT parameters as potential biomarkers in predicting long-term prognosis of localized clear cell renal cell carcinoma

verfasst von: Yichen Wang, Liqiang Cui, Jin Zhang, Lianyu Zhang, Jie Zhang, Xinming Zhao, Yan Chen

Erschienen in: Abdominal Radiology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to explore the relationship among baseline perfusion CT parameters, clinical, and pathological factors with post-nephrectomy long-term progression-free survival in localized clear cell renal cell carcinoma.

Materials and methods

This study retrospectively collected 127 patients from March 2005 to May 2007 who undertook perfusion CT. 61 patients were confirmed of pT1N0M0 or pT2N0M0 ccRCC. The mean follow-up time is 118.8 months (± 13.1 m, range 72–135 m). We compared clinical, pathological factors (gender, T stage, age, Fuhrmann grade, VEGF level, and MVD), and perfusion parameters before treatment [blood flow (BF), blood volume, mean transition time, and permeability surface-area product] between groups with post-nephrectomy metastasis and without metastasis. Association between covariates and progression-free survival (PFS) were analyzed using Cox proportional regression.

Results

Among 61 patients, 11 developed distant metastasis (10 in the lung, one in the bone). BF in metastatic group [429.1 (233.8, 570.1) ml/min/100 g] was significantly higher than non-metastatic group [214.3 (153.3, 376.5) ml/min/100 g] (p = 0.011). Metastatic group also had more patients with higher Fuhrmann grade. Multi-covariant Cox regression demonstrated T staging, Fuhrmann grade, and BF were significantly associated with PFS [hazard ratio (HR) 3.35, 3.08, and 1.006]. In another model, BF > 230 ml/min/100 g was associated with PFS (HR 12.90), along with T staging and Fuhrmann grade (HR 4.73, 3.69).

Conclusion

Baseline tumor BF is a potential biomarker in prediction long-term metastasis of localized ccRCC and may help screening for higher risk localized ccRCC patients who need personalized surveillance strategy after nephrectomy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines. J Natl Compr Canc Ne 2015, 13(2):151-159.CrossRef Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines. J Natl Compr Canc Ne 2015, 13(2):151-159.CrossRef
2.
Zurück zum Zitat Steven C, Uzzo RG, Mohamad E. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017, 198: 520-529.CrossRef Steven C, Uzzo RG, Mohamad E. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017, 198: 520-529.CrossRef
3.
Zurück zum Zitat Donat S M, Diaz M, Bishoff JT, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 2013, 190(2): 407-416.CrossRefPubMed Donat S M, Diaz M, Bishoff JT, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 2013, 190(2): 407-416.CrossRefPubMed
4.
Zurück zum Zitat Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 2007, 51(6): 1490-1501.CrossRefPubMed Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 2007, 51(6): 1490-1501.CrossRefPubMed
5.
Zurück zum Zitat Stewart SB, Thompson RH, Psutka SP, et al. Evaluation of the national comprehensive cancer network and American urological association renal cell carcinoma surveillance guidelines. J Clin Oncol 2014, 32(36):4059.CrossRefPubMedPubMedCentral Stewart SB, Thompson RH, Psutka SP, et al. Evaluation of the national comprehensive cancer network and American urological association renal cell carcinoma surveillance guidelines. J Clin Oncol 2014, 32(36):4059.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and clinic-pathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011, 78:1101-1106.CrossRefPubMed Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and clinic-pathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011, 78:1101-1106.CrossRefPubMed
7.
Zurück zum Zitat Eric HK, Seth AS. Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma. Urol Oncol-Semin Ori 2015, 33: 499-502.CrossRef Eric HK, Seth AS. Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma. Urol Oncol-Semin Ori 2015, 33: 499-502.CrossRef
8.
Zurück zum Zitat Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-2400.CrossRefPubMed Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-2400.CrossRefPubMed
9.
Zurück zum Zitat Thompson RH, Leibovich BC, Lohse CM, et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 2007; 177: 477-480.CrossRefPubMed Thompson RH, Leibovich BC, Lohse CM, et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 2007; 177: 477-480.CrossRefPubMed
10.
Zurück zum Zitat Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005;173:48-51.CrossRefPubMed Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005;173:48-51.CrossRefPubMed
11.
Zurück zum Zitat Karakiewicz PI, Suardi N, Capitanio U, et al. Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol 2009;182:2607-2612.CrossRefPubMed Karakiewicz PI, Suardi N, Capitanio U, et al. Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol 2009;182:2607-2612.CrossRefPubMed
12.
Zurück zum Zitat Ng CS, Wang X, Faria S C, et al. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. Am J Roentgenol 2010,194(1):166.CrossRef Ng CS, Wang X, Faria S C, et al. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. Am J Roentgenol 2010,194(1):166.CrossRef
13.
Zurück zum Zitat García-Figueiras R, Goh V J, Padhani AR, et al. CT perfusion in oncologic imaging: a useful tool? Am J Roentgenol 2013,200(1):8-19.CrossRef García-Figueiras R, Goh V J, Padhani AR, et al. CT perfusion in oncologic imaging: a useful tool? Am J Roentgenol 2013,200(1):8-19.CrossRef
14.
15.
Zurück zum Zitat Chen Y, Zhang J, Dai JR, et al. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging 2010,35:622-628.CrossRefPubMed Chen Y, Zhang J, Dai JR, et al. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging 2010,35:622-628.CrossRefPubMed
16.
Zurück zum Zitat Reiner C S, Roessle M, Thiesler T, et al. Computed tomography perfusion imaging of renal cell carcinoma: systematic comparison with histopathological angiogenic and prognostic markers. Invest Radiol 2013,48(4):183.CrossRef Reiner C S, Roessle M, Thiesler T, et al. Computed tomography perfusion imaging of renal cell carcinoma: systematic comparison with histopathological angiogenic and prognostic markers. Invest Radiol 2013,48(4):183.CrossRef
17.
Zurück zum Zitat Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-5799.CrossRefPubMed Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-5799.CrossRefPubMed
18.
Zurück zum Zitat Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113:1552-1558.CrossRefPubMed Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113:1552-1558.CrossRefPubMed
19.
Zurück zum Zitat Lughezzani G, Jeldres C, Isbarn H, et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol 2009;182:1287-1293.CrossRefPubMed Lughezzani G, Jeldres C, Isbarn H, et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol 2009;182:1287-1293.CrossRefPubMed
20.
Zurück zum Zitat Mains JR, Donskov F, Pedersen EM, et al. Dynamic Contrast-enhanced computed tomography-derived blood volume and blood flow correlate with patient outcome in metastatic renal cell carcinoma. Invest Radiol 2017,52(2):103.CrossRefPubMed Mains JR, Donskov F, Pedersen EM, et al. Dynamic Contrast-enhanced computed tomography-derived blood volume and blood flow correlate with patient outcome in metastatic renal cell carcinoma. Invest Radiol 2017,52(2):103.CrossRefPubMed
21.
Zurück zum Zitat Marcus CD, Ladammarcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009,72:217-238.CrossRefPubMed Marcus CD, Ladammarcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009,72:217-238.CrossRefPubMed
22.
Zurück zum Zitat Lassau N, Vilgrain V, Taieb S, et al. Evaluation with DCE-US of antiangiogenic treatments in 539 patients allowing the selection of one surrogate marker correlated to overall survival. Abstracts IEEE International Conference on Plasma Science. IEEE, 2012:2A-4-2A-4. Lassau N, Vilgrain V, Taieb S, et al. Evaluation with DCE-US of antiangiogenic treatments in 539 patients allowing the selection of one surrogate marker correlated to overall survival. Abstracts IEEE International Conference on Plasma Science. IEEE, 2012:2A-4-2A-4.
23.
Zurück zum Zitat Flaherty K, Rosen M, Heitjan D, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008,7:496-501.CrossRefPubMed Flaherty K, Rosen M, Heitjan D, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008,7:496-501.CrossRefPubMed
24.
Zurück zum Zitat Hahn O, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008,26:4572-4578.CrossRefPubMedPubMedCentral Hahn O, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008,26:4572-4578.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Sodickson A. Strategies for reducing radiation exposure in multi-detector row CT. Radiol Clin North Am 2012; 50:1-14.CrossRefPubMed Sodickson A. Strategies for reducing radiation exposure in multi-detector row CT. Radiol Clin North Am 2012; 50:1-14.CrossRefPubMed
26.
Zurück zum Zitat Rioux-Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007, 38:1489-1495.CrossRefPubMed Rioux-Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007, 38:1489-1495.CrossRefPubMed
27.
Zurück zum Zitat Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-347.CrossRefPubMed Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-347.CrossRefPubMed
28.
Zurück zum Zitat Klatte T, Bohm M, Nelius T, et al. Evaluation of perioperative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU Int 2007, 100: 209-214.CrossRefPubMed Klatte T, Bohm M, Nelius T, et al. Evaluation of perioperative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU Int 2007, 100: 209-214.CrossRefPubMed
29.
Zurück zum Zitat Lau WK, Cheville JC, Blute ML, et al. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 2002, 59(4): 532-537.CrossRefPubMed Lau WK, Cheville JC, Blute ML, et al. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 2002, 59(4): 532-537.CrossRefPubMed
Metadaten
Titel
Baseline perfusion CT parameters as potential biomarkers in predicting long-term prognosis of localized clear cell renal cell carcinoma
verfasst von
Yichen Wang
Liqiang Cui
Jin Zhang
Lianyu Zhang
Jie Zhang
Xinming Zhao
Yan Chen
Publikationsdatum
09.08.2019
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 10/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02087-z

Weitere Artikel der Ausgabe 10/2019

Abdominal Radiology 10/2019 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.